

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

William STERN

Date: August 21, 2008

Reissue Serial No.: 10/774,358

Confirmation no. 8408

Reissue Appln. Filed: February 5, 2004

Group Art Unit: 1616

Reissue of U.S. Patent No.: 6,440,392

Examiner: Mina Haghighatian

Issued: August 27, 2002

For: NASAL CALCITONIN FORMULATION

**VIA EFS WEB**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith is information, with a form listing the same for the convenience of the Examiner. Specifically, applicant encloses a hearing transcript and the following pleadings and Orders from *Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al.*, 06 Civ. 5571 (RPP):

1) November 6, 2007 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP);

2) February 4, 2008 Opinion and Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP);

3) February 20, 2008 Defendants' Notice of Motion in Support of Defendants' Motion For Reconsideration of the February 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al., 06 CIV 5571 (RPP);

4) February 20, 2008 Memorandum of Law in Support of Defendants' Motion for Reconsideration of the of the February 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al., 06 CIV 5571 (RPP);

5) Plaintiffs' Memorandum of Law in Opposition to Defendants' Motion for Reconsideration of the February 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al., 06 CIV 5571 (RPP); and


6) February 28, 2008 Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP).

I respectfully request that the information submitted be considered. The Patent and Trademark Office is authorized to charge the \$180 fee under 37 C.F.R. § 1.17(p), and any other amount owed, to Deposit Account No. 15-0700.

Respectfully submitted,

THIS CORRESPONDENCE IS BEING  
SUBMITTED ELECTRONICALLY  
THROUGH THE PATENT AND  
TRADEMARK OFFICE EFS FILING  
SYSTEM ON August 21, 2008

MAF:lm

  
\_\_\_\_\_  
Mark A. Farley  
Registration No.: 33,170  
OSTROLENK, FABER, GERB & SOFFEN, LLP  
1180 Avenue of the Americas  
New York, New York 10036-8403  
Telephone: (212) 382-0700